Corrigendum to “Investigation of the binding mode of clobenprobit at CXCR4 and development of novel anti-inflammatory compounds with enhanced activity and minimal antagonist effects” [Molecular Pharmacology 107 (2025) 100055]
Birgit Caspar(Centre National de la Recherche Scientifique), Jean‐Philippe Herbeuval(Centre National de la Recherche Scientifique), Stéphane Giorgiutti(Inserm), Nassima Bekaddour(Centre National de la Recherche Scientifique), Dominique Cathelin(Centre National de la Recherche Scientifique), Vincent Gies(Inserm), Anne‐Sophie Korganow(Inserm), Nicolas Pietrancosta(Délégation Paris 5), Ivana Stoilova(Centre National de la Recherche Scientifique), Vincent Rodeschini(Laboratoire d'Informatique en Images et Systèmes d'Information), Séverine Grinberg(Centre National de la Recherche Scientifique), Didier Roche(Laboratoire d'Informatique en Images et Systèmes d'Information)
Cited by 0
Related Papers
CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T<sub>H</sub>1 and T<sub>H</sub>9 cells
|Journal for ImmunoTherapy of Cancer|2022|80
Sarcoidosis-Related Uveitis: A Review
|Journal of Clinical Medicine|2023|51
CXCR4: from B-cell development to B cell–mediated diseases
|Life Science Alliance|2024|36
Current Transition Practice for Primary Immunodeficiencies and Autoinflammatory Diseases in Europe: a RITA-ERN Survey
|Journal of Clinical Immunology|2022|27